WHO Pharmaceuticals Newsletter No. 5, 2011.

Esta disponible con el siguiente contenido:

TABLE OF CONTENTS
Regulatory Matters
Aprotinin........................................................................................4
Asenapine maleate ...................................................................... 4
Ceftriaxone .................................................................................  4
Citalopram hydrobromide............................................................. 5
Clopidogrel and proton-pump inhibitors ................................... ..5
Dasatinib ......................................................................................5
Dronedarone .................................................................................. 6
Finasteride ..................................................................................... 7
Fluconazole .................................................................................... 7
Fusidic acid and Statins................................................................ 8
Gonadotropin-releasing hormone agonists................................. 8
Isotretinoin .................................................................................... ..9
Lenalidomide ..................................................................................9
Terpenic-based anti-cough medicines ........................................10
Tumour Necrosis Factor-alpha Blockers......................................10
Zoledronic acid ............................................................................ .10

Safety of medicines

Bevacizumab ................................................................................ 12
Bisphosphonates ..........................................................................12
Drospirenone-containing combined oral contraceptives ..........12
Gadolinium based contrast agents...............................................13
Ondansetron................................................................................. 13
Proton pump inhibitors..................................................................14
Quinine........................................................................................ 14
Uromitexan .................................................................................. 14
Venlafaxine ..................................................................................15

Feature
FIP pharmacovigilance seminar in India ....................................16



proximamente disponible en
http://www.who.int/entity/medicines/areas/quality_safety/safety_efficacy/PharmaNewsletter52011.pdf